Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EQ-8
- Development stage
- Preclinical
- Lead developer
- AxoProtego Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**EQ-8** is a preclinical **small molecule** neuroprotective candidate being developed by **AxoProteGo Therapeutics** for **multiple sclerosis** and **Parkinson's disease**. The compound is described as an **ethoxyquin-derived quinoline antioxidant** designed to improve **water solubility**, **oral bioavailability**, and **blood-brain barrier penetration** relative to ethoxyquin. Its proposed mechanism is **modulation of heat shock protein 90 chaperone activity**, with the therapeutic rationale of reducing neurodegenerative injury and promoting neuroprotection in central nervous system disease. AxoProteGo Therapeutics holds rights to ethoxyquin and related derivatives through a worldwide license from Johns Hopkins.
- Other names
- ethoxyquin derivative
02
Targets
HSP90 (Heat shock protein 90 chaperone complex)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on EQ-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EQ-8.